Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma

investigators plan to conduct a multicenter, prospective, randomized controlled, open, phase clinical study to compare the efficacy and safety of nimotuzumab with concurrent chemoradiation alone in elderly participants with advanced esophageal squamous cell carcinoma.

Trial Details

NCT ID
NCT06988956
Phase
PHASE2
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Nimotuzumab
  • Tegafur
  • radiotherapy
Locations (sample)
  • Nanjing, China|32.06167,118.77778

Key Eligibility Criteria

  • The subject volunteered to join the study, signed the informed consent form, had good compliance, and cooperated with the follow-up;
  • Age 70 or above, male or female;
  • The ECOG score is 0-1 point;
  • Oesophageal squamous cell carcinoma diagnosed by histology or cytology;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →